A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Breast cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 30 Jun 2016 Planned number of patients changed from 121 to 126.
- 05 May 2016 Status changed from not yet recruiting to recruiting.